It’s also active against B.1.351, which originated in South Africa, P.1, which originated in Brazil, and several other circulating variants. Intriguingly, adds Hansen, the antibody may also be effective at low enough doses to be administered as a shot, rather than an IV infusion. The company’s collaboration partner, pharmaceutical giant Eli Lilly, is submitting it to clinical trials, which entails a double-blind, randomized placebo trial with patients diagnosed with mild-to-moderate Covid. The 1404 antibody is going into clinical trials nearly a year after AbCellera and Lilly’s first Covid antibody treatment, bamlanivimab, went into clinical trials. Clinical trials showed that the combination therapy prevented hospitalizations and deaths by 87% in high-risk patients.
Source: Forbes May 04, 2021 10:30 UTC